Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SCIO Scios Inc. -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (1406)	10/8/2001 1:19:07 PM
From: Skywatcher	Respond to of 1477

This is another very interesting and promising news release...Holding on to this one for a while...at least till we pop back to the mid 20's...then will probably wait around until it takes a breather. Depends on the strength it shows in this market and what the continued revenue picture looks like. But from the first take, money seems to be coming in and the product moving well. CC

To: nigel bates who wrote (1406)	10/10/2001 12:20:04 PM
From: Skywatcher	Respond to of 1477

SUNNYVALE, Calif., Oct 10, 2001 /PRNewswire via COMTEX/ Scios Inc. today announced that the company has launched a firstofitskind nationwide registry to collect and analyze demographic and treatment data about patients hospitalized due to acutely decompensated heart failure. ADHERE, the Acute Decompensated HEart failure national REgistry, is expected to have a unique database of information of tens of thousands of patients gathered from approximately 200 hospitals over the next several years. ADHERE is overseen by an independent scientific advisory committee of nationally recognized heart failure experts. Scios created ADHERE to help clinicians better determine factors associated with improved clinical outcomes in acute decompensated heart failure, the primary cause of more than one million hospital admissions in the U.S. each year. "While acute heart failure is a leading cause of hospitalizations and heart failure is the single largest expense for Medicare, information and evidencebased treatment guidelines have been scarce for this fastgrowing medical condition," said Gregg Fonarow, M.D., Director, AhmansonUCLA Cardiomyopathy Center, University of California, Los Angeles and member of ADHERE's scientific advisory committee. "Current heart failure treatment guidelines are drawn from data on stable outpatients. There simply needs to be more data on patients hospitalized with acute heart failure, why they are admitted to the hospital, and what the optimal treatment strategy is. ADHERE will provide comprehensive demographic and treatment data on a wide range of hospitalized heart failure patients. By tracking how these very sick patients are treated over time, we can use this information to identify optimal treatment strategies for them and develop comprehensive acute heart failure guidelines." Roughly five million Americans suffer from heart failure, with 550,000 new cases diagnosed each year. There are approximately one million hospitalizations each year in the United States attributable specifically to acutely decompensated heart failure, which cost the healthcare system $15 billion annually. Another two million Americans are hospitalized each year with CHF as the secondary diagnosis. In the U.S., heart failure represents the most common cause of hospitalizations for patients over age 65. In ADHERE, acute care hospitals across the United States will contribute data securely while maintaining patient anonymity. Information will be collected on patient demographics, medical history, initial evaluation, hospital treatment and medications, resource utilization, procedures and disposition. ADHERE will assist hospitals with their internal quality improvement efforts by providing customized benchmark reports enabling each hospital to compare characteristics of its patient casemix and its patient evaluation and treatment practices with those of similar groups of hospitals, regionally and nationally. CC